ASCT after PD-1 blockade effective in refractory Hodgkin lymphoma

Autologous stem cell transplantation (ASCT) has yielded favourable outcomes in a high-risk cohort of patients with relapsed/refractory Hodgkin lymphoma (HL) who had previously been treated with anti-PD-1 therapy. The results were seen even among patients who were previously chemorefractory, according...

Autologous stem cell transplantation (ASCT) has yielded favourable outcomes in a high-risk cohort of patients with relapsed/refractory Hodgkin lymphoma (HL)...

Blood cancers

News in brief: Immunoglobulin shortage; New CAR T approach for non-Hodgkin’s B-cell lymphoma; Arthritis drug identified as good candidate for high-risk paediatric leukaemias

Immunoglobulin medicine shortage The TGA has advised that Flebogamma 5% DIF immunoglobulin, normal (human) will be unavailable until 11 September 2021. The products distributed by Grifols Australia Pty Ltd are listed as a critical shortage on the TGA’s medicine shortage information...

Immunoglobulin medicine shortage The TGA has advised that Flebogamma 5% DIF immunoglobulin, normal (human) will be unavailable until 11 September 2021. The...

Medicine

Revised COSA exercise guidelines embrace a more inclusive approach

The Clinical Oncology Society of Australia has overhauled its exercise guidelines to promote physical activity as a core part of cancer care. A COSA working group on exercise and cancer released the revised advice with little fanfare in March, after...

The Clinical Oncology Society of Australia has overhauled its exercise guidelines to promote physical activity as a core part of...

Blood cancers

TKI discontinuation in routine practice matches success in clinical trial settings for CML: Study

Discontinuation of tyrosine kinase inhibitor (TKI) therapy for chronic myeloid (CML) leukaemia patients is largely as successful in real-world clinical practice as it is in clinical trial settings, according to a new study conducted in Sweden. “Initially considered to be a...

Discontinuation of tyrosine kinase inhibitor (TKI) therapy for chronic myeloid (CML) leukaemia patients is largely as successful in real-world clinical...